Form D · Biotechnology
ZIOPHARM ONCOLOGY INC
Boston, MA · CIK 0001107421
Offering snapshot reported Sep 17, 2019 · SEC filing
- Reported sold
- $19.5M Offering amount: $19.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 12, 2019 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Sep 17, 2019 | Initial | $19,515,153 | No comparison | 1 | SEC filing |
| Aug 9, 2019 | Initial | $105,106,064 | No comparison | 5 | SEC filing |
| Nov 19, 2018 | Initial | $50,000,000 | No comparison | 7 | SEC filing |
| Jul 7, 2016 | Initial | $120,000,000 | No comparison | 1 | SEC filing |
| Jan 28, 2015 | Initial | $57,500,000 | No comparison | 1 | SEC filing |
| Nov 21, 2012 | Initial | $3,637 | No comparison | 1 | SEC filing |
| Jan 14, 2011 | Initial | $11,645,928 | No comparison | 1 | SEC filing |
| Sep 29, 2009 | Initial | $5,059,527 | No comparison | 26 | SEC filing |
| May 10, 2006 | Paper | Not reported | No comparison | Not reported | |
| Oct 24, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-348987
Consists of amounts which may be received by the Company upon the exercise of warrant (assuming no cashless exercises)
Source: Form D, filed Sep 17, 2019. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jason A. Amello | Executive |
| Richard E Bagley | Director, Executive |
| Caesar Belbel | Executive |
| Scott Braunstein | Director |
| Murray Brennan | Director |
| Jill Buck | Executive |
| James A. Cannon | Director |
| Laurence J.N. Cooper | Director, Executive |
| Eleanor De Groot | Executive |
| Elan Z. Ezickson | Director |
| Wyche Fowler | Director |
| Wyche Fowler, Jr. | Director |
| Gary S Fragin | Director |
| Robert Hadfield | Executive |
| Heidi Hagen | Director |
| Randal J. Kirk | Director |
| Kevin G. Lafond | Executive |
| Francois Lebel | Executive |
| Jonathan Lewis | Director, Executive |
| David M. Mauney | Executive |
| Timothy Mc Inerney | Director |
| Douglas W. Pagan | Director |
| Sath Shukla | Executive |
| Scott Tarriff | Director |
| Michael Weiser | Director |
| Hagop Youssoufian | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
One First Avenue Parris Building 34, Navy Yard Plaza
Boston, MA, 02129
Boston, MA, 02129